US Patent Granted for SoluPro™ Technology

US Patent Granted for SoluPro™ Technology

Vancouver, WA – April 11, 2017 United States Patent No. 9,617,335 was issued today to AbSci, an industry leader in biomanufacturing innovation, for its SoluPro™ protein expression system, which produces complex therapeutic proteins at unparalleled yield and throughput...

read more
AbSci Receives European Patent on its SoluPro™ Expression Platform

AbSci Receives European Patent on its SoluPro™ Expression Platform

AbSci a global leader in biomanufacturing technologies, was granted a European regional patent today for its SoluPro™ protein production technology. “Many years of discovery went into developing the SoluPro™ expression platform. The SoluPro™ technology provides a revolutionary solution to one of biomanufacturing’s ongoing challenges …

read more
AbSci Announces New Headquarters in Downtown Vancouver Washington

AbSci Announces New Headquarters in Downtown Vancouver Washington

AbSci announced today that the company has finalized a lease agreement to relocate its headquarters to the new Hudson Building in downtown Vancouver, WA. AbSci expects to begin renovations by the beginning of September, and plans to take occupancy of the state-of-the-art lab facility by Q4 of this year, where the company will continue to develop and commercialize its revolutionary protein production technology.

read more

AbSci Secures Series A Funding

PORTLAND, Ore., April 25, 2016 /PRNewswire/ -- AbSci, a global leader in soluble microbial protein expression has secured $5.1M in Series A financing led by Phoenix Venture Partners (PVP). Funding will accelerate commercialization of AbSci's SoluPro™ protein...

read more